Eli Lilly and Company and Incyte Corp. announced results from the Phase 3 RA-BEACON study of baricitinib in patients with active rheumatoid arthritis (RA). Baricitinib is an orally available Janus kinase (JAK) 1 and JAK2 inhibitor being studied for use in the treatment of certain autoimmune conditions, including RA.

The RA-BEACON study included 527 patients with moderately-to-severely active RA who previously failed one or more tumor necrosis factor (TNF) inhibitors and who were taking stable doses of conventional disease-modifying anti-rheumatic drug (cDMARD) therapy. Patients received either one of two doses of once daily baricitinib or placebo in addition to their background conventional disease-modifying anti-rheumatic drug therapy (cDMARDs). Results demonstrated that the primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment has been met.

RELATED: Oral Contraceptives May Slow RA Progression

The results of several ongoing Phase 3 studies conducted by Lilly and Incyte will be announced in 2015.

For more information visit Lilly.com or Incyte.com.